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Negative Regulation of Yeast WASp
by Two SH3 Domain-Containing Proteins
The rate-limiting step for de novo actin filament as-
sembly is nucleation, which requires the formation of
actin dimers and trimers (reviewed in [1]). A key cellular
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University of California, Berkeley factor involved in actin nucleation is the conserved
Arp2/3 complex. Upon interaction with an activator (alsoBerkeley, California 94720
2Department of Biology and Rosenstiel Center called a nucleation-promoting factor [2]), Arp2/3 com-
plex is thought to undergo conformational changes thatBrandeis University
Waltham, Massachusetts 02454 result in rearrangement of the Arp2 and Arp3 subunits
to form an actin dimer-like nucleus for polymerization.
These activators include ActA, WASp/SCAR/WAVE fam-
ily members, cortactin, Abp1, type I myosins, and Pan1Summary
(reviewed in [2]). Regulation of activators determines
when and where in cells Arp2/3 complex nucleates actinBackground: WASp family proteins promote actin fila-
assembly. WASp and SCAR/WAVE family members arement assembly by activating Arp2/3 complex and are
thought to stimulate Arp2/3 complex via their WA do-regulated spatially and temporally to assemble special-
mains (WH2 [WASp homology 2] and A [acidic]). In WASpized actin structures used in diverse cellular processes.
proteins, the activity of the WA domain is inhibited bySome WASp family members are autoinhibited until
intramolecular associations between the GTPase bind-bound by activating ligands; however, regulation of the
ing domain located in the amino terminal half of thebudding yeast WASp homolog (Las17/Bee1) has not yet
protein and acidic sequences located in the WA domain.been explored.
Ligands of WASp proteins, including Cdc42, PIP2, andResults: We isolated full-length Las17 and character-
SH3 domain-containing proteins, relieve this autoinhibi-ized its biochemical activities on yeast Arp2/3 complex.
tion, allowing WASp to interact with Arp2/3 complexPurified Las17 was not autoinhibited; in this respect, it
[3–6]. In contrast, SCAR/WAVE family members do notis more similar to SCAR/WAVE than to WASp proteins.
contain a G protein binding domain and are not autoin-Las17 was a much stronger activator of Arp2/3 complex
hibited [7, 8]. One family member, WAVE-1, is negativelythan its carboxyl-terminal (WA) fragment. In addition,
regulated in trans when bound to PIR121 and Nap125.actin polymerization stimulated by Las17-Arp2/3 was
Upon Rac1 or Nck binding, WAVE-1 complex dissoci-much less sensitive to the inhibitory effects of profilin
ates, releasing WAVE-1 to activate Arp2/3 complex [8].compared to polymerization stimulated by WA-Arp2/3.
WASp family members are defined by the presenceTwo SH3 domain-containing binding partners of Las17,
of an amino-terminal WH1 (WASp Homology 1) domain,Sla1 and Bbc1, were purified and were shown to cooper-
whereas SCAR/WAVE proteins have an SHD (Scar Ho-ate in inhibiting Las17 activity. The two SLA1 SH3 do-
mology Domain). Budding yeast contains a singlemains required for this inhibitory activity in vitro were
WASp/SCAR homolog (Las17/Bee1), which is requiredalso required in vivo, in combination with BBC1, for cell
for normal yeast cell growth, actin organization, endocy-viability and normal actin organization.
tosis, and morphogenesis [9, 10]. Las17 resemblesConclusions: Full-length Las17 is not autoinhibited and
WASp proteins in its overall domain organization andactivates Arp2/3 complex more strongly than its WA
contains a WH1 domain, but has no obvious G proteindomain alone, revealing an important role for the Las17
binding motif and does not bind to Cdc42 directly [11].amino terminus in Arp2/3 complex activation. Two of
Therefore, the mechanisms regulating Las17 activitythe SH3 domain-containing ligands of Las17, Sla1 and
have remained a mystery. Recent studies have identifiedBbc1, cooperate to inhibit Las17 activity in vitro and are
numerous Las17 ligands that may control its activity.required for a shared function in actin organization in
The WH1 domain of Las17 binds strongly to Vrp1, thevivo. Our results show that, like SCAR/WAVE, WASp
yeast homolog of WIP (WASp-interacting protein) [11,proteins can be controlled by negative regulation
12]. The proline-rich region of Las17 binds to SH3 do-through the combined actions of multiple ligands.
main-containing proteins, including Sla1, Bbc1/Mti1,
Bzz1/Lsb7, Myo3/5, Lsb1, Lsb2, Pin3, Ysc84, Sho1, and
Introduction Rvs167 [9, 10, 13–16]. Bzz1 acts upstream of Las17-
dependent actin assembly in cell extracts; this finding
The actin cytoskeleton generates forces that are harnes- is consistent with a positive regulatory role for Bzz1 on
sed for diverse cellular processes such as cell motility, Las17 activity [17]. The roles of other Las17 ligands in
cytokinesis, exocytosis, and endocytosis. These pro- its function have not yet been addressed. The carboxyl
cesses are dynamic and require rapid assembly and terminus of Las17 contains a WA domain that is suffi-
disassembly of actin structures. Numerous actin binding cient for Arp2/3 complex binding and activation in vitro
proteins control actin dynamics, and their combined [18]. However, deletion of this domain causes a far less
activities produce actin structures specialized for differ- severe phenotype than deletion of the entire gene. One
ent cellular functions. explanation for this result is that the Las17 amino termi-
nus may act as a scaffold for Las17 ligands that also
activate Arp2/3 complex (e.g., Myo3/5 and Vrp1 [11, 14]).*Correspondence: drubin@uclink4.berkeley.edu
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Figure 1. Proteins Used in This Study
(A) Domain structure of the proteins used in
this study.
(B) Coomassie-stained 12.5% (left) and 10%
(right) acrylamide gels of purified proteins.
Here, we characterized the activity of full-length Las17 nM [19]). In addition, Las17 activity was dramatically
stronger than its carboxyl terminus alone (WA domain).on Arp2/3 complex in the presence and absence of two
Las17 ligands, Bbc1 and Sla1. Las17 had constitutive In contrast, concentrations of full-length Las17 that
strongly stimulated actin assembly in the presence ofactivity (nonautoinhibited) and was negatively regulated
by Bbc1 and Sla1. Thus, Las17 function is controlled by Arp2/3 complex had no effect on the assembly rate of
actin alone (Figure 2B).inhibitory ligands and in this way behaves more like
SCAR/WAVE than WASp proteins. Since the WA domain used in Figure 2A was purified
from E. coli, while full-length Las17 was purified from
yeast, we considered the possibility that activity differ-Results and Discussion
ences might be due to the expression source. Therefore,
we purified from yeast a carboxyl-terminal 106 aminoPurified Full-Length Las17 Is Highly Active
and Is Not Autoinhibited acid fragment of Las17 by the same method used to
purify full-length Las17. This WA domain had a similarTo investigate the regulation of Las17 activity, we puri-
fied full-length Las17 protein from yeast overexpressing activity to the WA domain purified from E. coli (not
shown), suggesting that the strong activity of Las17 isLas17 fused to nine repeats of the myc epitope tag. The
tagged Las17 was affinity purified by using anti-myc not due to its expression source, or to the residual amino
acids left on the recombinant protein after cleavage fromantibody-coated beads, and the tag was cleaved by TEV
protease digestion, leaving the sequence AAAENLYFQ the myc epitope tag. These data suggest that Las17
sequences amino terminal to the WA domain play anappended to the carboxyl terminus of Las17 (Figure 1).
We tested the activity of Las17 on actin assembly in the important role in Arp2/3 complex activation.
presence and absence of purified yeast Arp2/3 complex.
In contrast to other WASp family members, Las17 was Effects of Profilin on Las17-Arp2/3 Complex-Induced
Actin Filament Nucleationnot autoinhibited (Figure 2A). Full-length Las17 potently
activated Arp2/3 complex with half-maximal activation Profilin is an actin monomer binding protein that steri-
cally blocks assembly of actin monomers onto theat 4.2 nM (Figures 2B and 2C), 100-fold stronger than
the untagged mammalian WASp-WA fragment on mam- pointed end of the filament and suppresses spontane-
ous nucleation of actin filaments from free monomersmalian Arp2/3 complex (half-maximal activation at 425
Current Biology
1002
(reviewed in [1]). High concentrations of profilin inhibit
Arp2/3 complex-mediated actin assembly stimulated by
the WA domains of SCAR or Las17 ([7] and Figure 3A).
We used this observation to test whether activation of
Arp2/3 complex by full-length Las17 works by a different
mechanism than WA domain activation of Arp2/3 com-
plex. Concentrations of profilin that strongly inhibited
maximal WA domain activation of Arp2/3 complex had
no effect on full-length Las17-mediated actin assembly
(Figure 3A). Since Las17 contains several putative pro-
filin binding poly-proline sequences, we tested whether
direct binding of profilin to Las17 might alleviate the
negative effects of profilin on actin assembly. Arp2/3
complex stimulation by Las17 was tested in the pres-
ence of a mutant profilin (Pfy1-19, containing the muta-
tion Y120D) that has at least ten-fold reduced poly-
proline binding [20]. Wild-type yeast profilin binds to
extended poly-proline stretches (Pro50) with a dissocia-
tion constant of 5.5 M [21]. Therefore, Pfy1-19 should
have a dissociation constant above 50 M. Pfy1-19 in-
hibited the assembly of actin alone, similar to wild-type
profilin (data not shown and [20]), but had no inhibitory
effects on Las17-mediated actin assembly in the range
of Pfy1-19 concentrations tested (Figure 3A). These data
suggest that Las17-profilin binding does not alleviate
inhibition of actin assembly by profilin. One caveat to
this interpretation is that Pfy1 and Pfy1-19 may have a
much higher affinity for Las17 than for poly-proline,
since mammalian profilin-I has a higher affinity for
N-WASp than for poly-proline [22]. However, no associa-
tion has yet been detected between Las17 and profilin
in multiple efforts to find Las17-interacting partners
(e.g., [10, 15, 23]).
Arp2/3 complex activation is thought to be mediated
by a combination of two inputs: conformational change
induced by binding of Arp2/3 complex to the sides of
actin filaments, and conformational change induced by
activator binding (reviewed in [2]). To explain the effects
of profilin on WA-Arp2/3 complex, we considered the
possibility that by preventing spontaneous formation of
actin filaments at early stages of assembly, profilin might
inhibit WA-mediated Arp2/3 complex activation. To test
this model, we added preformed actin filaments to WA-
activated Arp2/3 complex. While preformed filaments
eliminated the lag phase of actin polymerization, they
did not overcome the inhibitory effects of profilin (Figure
3B); this finding suggests that profilin does not inhibit
WA-Arp2/3 complex by suppressing spontaneous fila-
ment polymerization.
What then accounts for the inhibition of WA-Arp2/3
complex by profilin? Current models for activation of
Arp2/3 complex by WASp and SCAR/WAVE proteins
suggest that binding of WA to actin monomers is crucial
for nucleation (reviewed in [2]). It is possible that high
Figure 2. Activity of Full-Length Las17 concentrations of profilin compete with WA for binding
(A and B) A total of 3 M rabbit muscle actin (1% pyrene labeled) actin monomers and thus suppress WA activation of
was polymerized in the presence of the indicated concentrations Arp2/3 complex. Consistent with this model, the addi-
of Arp2/3 complex, Las17, or the WA fragment of Las17. tion of actin monomers in excess to profilin overcomes
(C) The concentration of barbed ends was calculated by using the
the inhibitory effect of profilin on WA-Arp2/3 complexformula [barbed ends] rate of polymerization/(rate constant [actin
[24]. Further, the WA domain of WASp directly competesmonomers]). Arbitrary fluorescence units were converted to a con-
with profilin for actin monomer binding and has a similarcentration of filamentous actin by assuming a final actin filament
concentration of 2.9 M. The rate constant for rabbit muscle actin binding affinity for actin monomers (Kd 0.6M) to profilin
polymerization at pH 7.5 is 8.7 M1s1 [56]. (Kd 0.2 M) [19]. Alternatively, since profilin can bind
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Figure 3. Effects of Profilin on Las17 Activation of Arp2/3 Complex
(A–C) (A) A total of 3.5 M or (B and C) 3 M rabbit muscle actin with a 1% pyrene label was polymerized in the presence of the indicated
concentrations of Arp2/3 complex, Las17, the Las17 WA fragment, preformed actin filaments, or profilin.
directly to Arp2/3 complex (Kd 7 M), it may compete Sla1 and Bbc1 Inhibit Las17 Activity
on Arp2/3 Complexwith the WA domain for Arp2/3 complex binding [25].
In contrast, full-length Las17 may have a significantly Since purified Las17, like purified WAVE, is not autoin-
hibited, we tested whether Las17 might be regulated byhigher affinity for actin monomers or Arp2/3 complex
than its WA domain alone and therefore may efficiently trans-acting inhibitory ligands, as has been shown for
WAVE-1 [8, 26]. Sla1 interacts with Las17 by the two-displace profilin from these ligands.
To evaluate this model, we tested whether profilin hybrid assay [16] and coimmunoprecipitation [9], and is
required for normal actin organization and endocytosiscould compete with subsaturating concentrations of
Las17 (5 nM, subsaturating in Figure 2B). Profilin could in vivo [27, 28] and for actin assembly in permeabilized
yeast cells [29]. Sla1 has three amino-terminal SH3 do-inhibit subsaturating full-length Las17, and high concen-
trations of profilin had inhibitory effects on saturating mains, a central region with SHD1 and SHD2 (Sla1 ho-
mology) domains, conserved in all fungal Sla1 homo-Las17 (Figure 3C). Therefore, profilin has similar but much
less potent inhibitory effects on Las17-Arp2/3 complex logs, and carboxyl-terminal repeats similar to regions
of the yeast Eps15 homolog Pan1 (Figure 1A; also [30,compared to WA-Arp2/3 complex. These results suggest
that full-length Las17 acts by a similar mechanism as 31]). Bbc1/Mti1 is another protein that interacts with
Las17 by the two-hybrid assay and by coimmunoprecip-the WA domain but has a higher affinity for actin mono-
mers or for Arp2/3 complex. itation [16] and was recently shown to have a role geneti-
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cally redundant with that of Sla1 [32]. Therefore, we
reasoned that Sla1 and Bbc1 might have similar effects
on Las17 activity.
Sla1, Bbc1, and a fragment of Sla1 containing its three
SH3 domains were purified from yeast by the same
method used to purify Las17 (Figure 1). Saturating
amounts of Sla1SH3 inhibited Las17-Arp2/3 complex
activity by 39%, with a half-maximal concentration of
200 nM Sla1SH3 (Figure 4A). This value is consistent
with the tightest reported binding affinities of SH3 do-
mains for their ligands [33]. The SH3 domain-containing
fragment of Sla1 proved to be significantly more amena-
ble to purification and manipulation than full-length Sla1,
and since both Sla1 constructs had similar activity on
Las17-Arp2/3 complex (not shown), only data using the
Sla1 fragment (referred to as Sla1SH3) are shown. Bbc1
also had an inhibitory activity on Las17; 150 nM Bbc1
inhibited Las17 activation of Arp2/3 complex by 28%
(Figure 4B). The combination of Sla1SH3 and Bbc1 to-
gether had a more pronounced effect (63% maximum,
Figure 4B) than could be achieved by using Sla1 alone.
By comparison, Sla1SH3 and Bbc1 had no effect on
WA-Arp2/3 complex activity, indicating that their effects
require sequences in Las17 amino terminal to the WA
domain. We were unable to purify sufficient amounts of
Bbc1 to saturate its inhibitory effect on Las17. However,
250 nM Bbc1 had an equally strong additive effect with
both subsaturating (0.5 M) and saturating (2 M)
amounts of Sla1SH3 (see the Supplemental Data avail-
able with this article online). This suggests that Sla1 and
Bbc1 act through distinct binding sites on Las17. 200 nM
Abp1 with mutated acidic sequences (and thus unable to
stimulate Arp2/3 complex [34]), but with an intact SH3
domain, had no effect on Las17 activation of Arp2/3
complex (not shown). Thus, the activities of Sla1 and
Bbc1 on Las17 require specific SH3 domain interactions.
To define which SH3 domain(s) in Sla1 are required
for inhibition of Las17-Arp2/3 complex, we generated
point mutations in the conserved tryptophan residues
of each of the three Sla1 SH3 domains (W41A, W108A,
and W391A). These types of mutations have been shown
to abolish SH3 domain interactions with proline-rich tar-
gets [35]. Inactivation of either the first (Sla1SH3-1*) or
second (Sla1SH3-2*) SH3 domain of Sla1 alone dimin-
ished the inhibition of Las17 (Figure 4C). Disruption of
the first and second SH3 domains together (Sla1SH3-
12*) inactivated Sla1 to a similar extent as disruption
of either SH3 domain alone. In contrast, disruption of Figure 4. Effects of Sla1 and Bbc1 on Las17 Activity
the third SH3 domain (Sla1SH3-3*) had little effect (Fig- (A–C) (A) A total of 3 M or (B and C) 3.5 M rabbit muscle actin (1%
ure 4C), further supporting the specificity of inhibition pyrene labeled) was polymerized in the presence of the indicated
concentrations of Arp2/3 complex, Las17, Bbc1, or the Sla1 frag-of Las17 activity by the first and second SH3 domains
ment. (A) Sla1 inhibits Las17 at a half-maximal concentration of 200of Sla1. Finally, disruption of all three SH3 domains of
nM Sla1. (B) Sla1 and Bbc1 have additive inhibitory effects on Las17.Sla1 caused approximately the same level of inhibition
(C) The first and second SH3 domains of Sla1 are required for inhibi-of Las17 as disruption of the first two SH3 domains;
tion of Las17 activity on Arp2/3 complex. Arp2/3 complex was used
thus, any residual inhibition in these mutants is not due at 15 nM, Las17 was used at 15nM, and the Sla1 SH3 fragments
to activity of the third SH3 domain of Sla1 (Figure 4C). were used at 1 M. Percent inhibition was normalized to the activity
These results were unexpected, given that a recent anal- of wild-type Sla1SH3. The bars show the average and standard
deviation from at least two independent experiments.ysis of yeast SH3 domain interactions predicted that the
third SH3 domain of Sla1 and the SH3 domain of Bbc1
can interact with the same proline-rich site on Las17 of Sla1 make distinct interactions with Las17, since their
[16]. However, the first and second SH3 domains of Sla1 activities are additive even when using amounts of Sla1
were not included in the above-mentioned study. Our that saturate its activity alone (see the Supplemental
Data).results show that Bbc1 and the first two SH3 domains
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Sla1SH3 and Bbc1 could act together by recruiting Sla1 was sufficient to disrupt inhibition of Las17 in vitro,
whereas either single mutant alone caused a less severeeach other to Las17, thus increasing overall affinity or
inhibitory activity. Indeed, Bbc1 contains a recognition phenotype than the SH3-12* double mutant in vivo.
One possible explanation for this discrepancy is thatsite for the third SH3 domain of Sla1, and Sla1 contains
a proline-rich recognition site for the SH3 domain of our in vitro assay is not sensitive enough to measure
differences in activity between the double and singleBbc1 [16]. To test this hypothesis, we compared Las17
activity in the presence of Bbc1 and wild-type Sla1SH3 mutants. Alternatively, other ligands of Las17 may inhibit
its activity in the cell enough to compensate for disrup-or Sla1SH3-3*. Bbc1 had the same additive inhibitory
effect with Sla1SH3-3* as with wild-type Sla1SH3; this tion of either SLA1 SH3 domain alone, but not for disrup-
tion of both SH3 domains. A third and related explana-finding suggests that the third SH3 domain of Sla1 is
not involved in the additive inhibition (not shown). tion is that direct ligands of the first or second SH3
domain of Sla1 may provide compensatory inhibition of
Las17. The first and second SH3 domains of Sla1 were
SLA1 and BBC1 Share an Overlapping Role In Vivo not included in a recent genome-wide analysis of SH3
Bbc1 is a component of Las17/myosin I/Vrp1 complex domain interactions [16]. However, a genome-wide two-
and binds to the SH3 domain of myosin I [11, 36]. The hybrid interaction study between full-length proteins
bbc1 null mutation alone has no growth phenotype but suggested binding of Sla1 to two other Las17 ligands,
synthetically compromises the growth of other mutants, Rvs167 and Ysc84 [13]. These interactions were not
including sla1, sac6, bni1, cap1, and sla2 [32, 36]. Since predicted by the binding properties of Sla1SH3-3 [16];
Sla1 and Bbc1 showed similar inhibitory effects on Las17- this leaves open the possibility that Rvs167 and Ysc84
Arp2/3 complex, we tested whether their synthetic could bind to the first and/or second SH3 domain of
growth defects in vivo might correlate with their bio- Sla1 and regulate Las17.
chemical activities. Our data support the model that there is a shared in
We generated sla1 bbc1 double mutants and found vivo function for Sla1 and Bbc1 mediated by the first
that they were viable at room temperature but were more two SH3 domains of Sla1 (Figure 5). Our genetic data
temperature sensitive at 34C and 37C than either single correlate with the biochemical data showing that the
mutant (data not shown). Low-copy plasmids were used first and second SH3 domains of Sla1 are required for
to express full-length sla1 mutants with SH3 domain its inhibitory activity on Las17 (Figure 4C). In previous
disruptions that impair activities on Las17 in vitro. Muta- studies, no role was found for Sla1 SH3 domains in
tion of any combination of SH3 domains of SLA1 in rescuing the sla1 null phenotype or the synthetic lethality
otherwise wild-type cells had no effect on cell growth or between sla1 and abp1 [30]. Thus, our data define the
actin organization (not shown); this finding is consistent first in vivo function for the SH3 domains of Sla1 and
with previous studies [30]. However, mutation of either suggest that the first two SH3 domains of Sla1 in combi-
the first or second SH3 domains of SLA1 in combination nation with Bbc1 negatively regulate Las17.
with the bbc1 null mutation reduced growth at 37C,
and mutation of both of these SLA1 SH3 domains in
combination with bbc1 caused lethality at 37C (Figure Function and Regulation of Las17 In Vivo
We have shown that Las17 has a much stronger ability5A). These double mutant cells were large and round,
which is a phenotype common for mutants in actin- to activate Arp2/3 complex than its carboxyl-terminal
WA fragment and that full-length Las17 purified fromassociated proteins (Figure 5B) [37]. In contrast, muta-
tion of the third SH3 domain of SLA1 in bbc1 cells had yeast by the method described here is not autoinhibited.
Since mammalian WASp, for unknown reasons, can beno effect. We examined actin organization in sla1 bbc1
cells by rhodamine phalloidin staining. In SLA1 bbc1 purified in both inhibited and uninhibited forms [4, 38],
it remains possible that Las17 might be autoregulatedcells, cortical actin patches are polarized in the bud.
Mutation of either the first or second SH3 domains of under certain conditions. However, the absence of a G
protein binding motif in Las17 is more consistent withSLA1 in bbc1cells had no discernable effect on cortical
actin patch actin organization, but the sla1SH3-12* it being regulated by a mechanism similar to that re-
ported for SCAR/WAVE than for WASp proteins. Thismutation resulted in large, aberrant filamentous actin
clumps, similar to the sla1 bbc1 double mutant phe- also raises the possibility that WASp proteins in other
organisms may be subject to negative regulation. Re-notype (Figure 5B). This actin phenotype is much more
severe than that of sla1 BBC1 cells (data not shown gardless of whether Las17 can be autoinhibited, our
genetic and biochemical data define a combined inhibi-and [30]). All SLA1 mutants fully complement the pheno-
type of the sla1 null mutant (not shown), indicating that tory function for Sla1 and Bbc1 on Las17-Arp2/3 com-
plex and the first in vivo function for Sla1 SH3 domains.the mutant proteins are expressed.
To confirm that the shared function of SLA1 and BBC1 What is the specific function of Las17 in cells? Local-
ization of Las17, myosin I, and Vrp1 to cortical patcheswas not simply localization of Las17 to actin structures,
we examined Las17-GFP localization in bbc1 sla1SH3- is maintained after treatment of cells with latrunculin-A,
an actin monomer-sequestering agent that leads to net12* cells. Las17-GFP colocalized with actin in large,
aberrant clumps (Figure 5C), suggesting that the func- actin depolymerization [10, 12, 39]. Therefore, these
components may function upstream of actin assemblytion of the first two SH3 domains of Sla1 is not to localize
Las17 to actin structures, but instead to regulate its in vivo; this finding is consistent with their requirement
for actin assembly in the permeabilized cell assay [15].activity.
Mutation of either the first or second SH3 domain of In addition, Arp2/3 complex, myosin I, and Vrp1 are
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Figure 5. Genetic Interactions between SLA1 and BBC1
(A) DDY2513 (sla1 bbc1 ) cells containing SLA1 plasmids were grown to saturation in selective media, plated in ten-fold serial dilutions on
selective media, and grown at the indicated temperatures for 4 days.
(B) Rhodamine-phalloidin staining and phase microscopy of sla1 bbc1 mutant cells shifted to 37C for 2 hr.
(C) Las17::GFP localization (live cells, top two panels) and Las17::GFP/actin colocalization (fixed cells, bottom four panels) in sla1 bbc1 cells
shifted to 37C for 2 hr.
sla1::HIS3, bbc1::KANMX, LAS17::GFP::HISMX, his3, leu2, lys2-required for directional motility of cortical actin patches,
801, ura3) was constructed by integrating a carboxyl-terminal GFPwhich may be driven by actin polymerization [40–42].
tag onto the endogenous LAS17 gene as described [47]. SLA1 plas-Recently, it was shown that not all actin patches contain
mids were generated by ligating between the XhoI and NotI sites
Sla1 and that Sla1-containing patches move more of pRS315 [48] a fragment of genomic DNA containing 500 base
slowly than Sla1-free patches [28]. These observations pairs upstream and 493 base pairs downstream of the SLA1 open
reading frame. Overexpression plasmids for protein purificationare consistent with an inhibitory role for Sla1 on actin
were generated by ligating open reading frames (as designated inpolymerization-driven patch motility. Our results sug-
Figure 1A) into a modified pRS426 [49] containing the GAL1-10gest that this inhibition may occur directly through Sla1
promoter, a TEV protease recognition site, and nine copies of theSH3 domain interactions with Las17.
myc epitope. Site-directed mutagenesis was performed by using
In yeast and mammals, cortical actin is required for the Quickchange (Stratagene) approach. All plasmid constructions
endocytosis, but its precise role in this process has not were verified by DNA sequencing. For plasmid rescue assays, yeast
transformants of strain DDY2513 (MATa sla1::HIS3, bbc1::been defined [43]. The SHD1 region of Sla1 binds to
KANMX, las17::URA3, his3, leu2, lys2-801, ura3; pRS314-LAS17)receptors targeted for actin-mediated endocytosis [44],
containing the indicated plasmid constructions were grown to satu-and the carboxyl-terminal repeats of Sla1 form a com-
ration in selective media and were plated in a ten-fold serial dilutionplex with the endocytic proteins Pan1 (which can acti-
on selective media for 4 days at the indicated temperature.
vate Arp2/3 complex [45]) and End3 [31]. In the future,
it will be important to test how physical interactions in Protein Expression and Purification
Sla1-End3-Pan1, Bbc1-Vrp1-myosin I, and Sla1-recep- BJ2168 [50] or R314 [51] yeast cells expressing the relevant plasmid
were grown to saturation in 100 ml synthetic media with 2% w/vtor complexes affect Las17 activities on Arp2/3 complex.
dextrose and no uracil. This inoculum was added to 2 liters of syn-
thetic media with 2% w/v raffinose (or dextrose for R314) and noExperimental Procedures
uracil and was grown to an OD600 of 1.0. Cultures were then induced
with 40 g bacto-peptone, 20 g yeast extract, and a final concentra-Yeast Strains, Media, Plasmid Constructions,
and DNA Manipulations tion of 2% w/v galactose for 8–16 hr. Cells were harvested by centrif-
ugation, washed with 500 ml water, resuspended in 1/2 v/w ratio ofStandard methods were employed for DNA manipulations, growth,
and transformation of yeast [46]. The LAS17::GFP strain (MATa water, frozen in 50 l drops in liquid N2, and lysed as described [52].
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To purify TEV-myc-tagged proteins, cell powders were thawed in 2. Welch, M.D., and Mullins, R.D. (2002). Cellular control of actin
nucleation. Annu. Rev. Cell Dev. Biol. 18, 247–288.1/4 v/w ratio of 100 mM HEPES (pH 7.5), 5 mM EDTA, and protease
inhibitors (final concentration of 0.5 g/ml each of antipain, leupep- 3. Rohatgi, R., Ho, H.Y., and Kirschner, M.W. (2000). Mechanism
of N-WASP activation by CDC42 and phosphatidylinositoltin, pepstatin A, chymostatin, aprotinin and 1 mM PMSF). Triton
X-100 was then added to a final concentration of 0.5% v/v. A total 4, 5-bisphosphate. J. Cell Biol. 150, 1299–1310.
4. Higgs, H.N., and Pollard, T.D. (2000). Activation by Cdc42 andof 18 ml crude lysate was centrifuged for 20 min at 80,000 rpm in
a TLA100.3 rotor (Beckman). The cleared supernatant was loaded PIP(2) of Wiskott-Aldrich syndrome protein (WASp) stimulates
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